The Effects of NAD on Brain Function and Cognition
Latest Information Update: 28 Dec 2022
Price :
$35 *
At a glance
- Drugs Nicotinamide riboside (Primary)
- Indications Mild cognitive impairment
- Focus Therapeutic Use
- 27 Dec 2022 According to a ChromaDex media release, results from the trial were published in the journal Nature Communications in 2018.
- 31 Aug 2021 Status changed from active, no longer recruiting to completed.
- 14 Jul 2021 Planned End Date changed from 1 Jun 2021 to 1 Dec 2021.